Public Company

Precision BioSciences, Inc.

About

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform – a versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist.

Overview

Founded 2006
Type Public
Location North Carolina, USA

Stock

DTIL $1.18 1.29% $0.02

Latest News

Coinbase To $80? Plus Deutsche Bank Cuts PT On This Stock By 80% Nov 10, 2022 Benzinga Citigroup cut the price target on Coinbase Global, Inc. (NASDAQ: COIN) from $105 to $80. Citigroup analyst Peter Christiansen maintained a Buy rating on the...
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates Nov 08, 2022 Zacks Investment Research Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to...
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos Oct 19, 2022 Zacks Investment Research Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount...
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus Aug 10, 2022 Zacks Investment Research Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for...
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss Aug 10, 2022 Zacks Investment Research Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired...